Drug candidate stops extra bone growth in animal model of rare, genetic disease

Posted by on April 13, 2016 3:35 pm
Categories: health

New preclinical research provides support to a drug that has been repurposed to possibly treat a rare and extremely disabling genetic bone disease, particularly in children. In that disease, fibrodysplasia ossificans progressiva (FOP), a mutation triggers bone growth in muscles, alters skeletal bone formation, and limits motion, breathing, and swallowing, among a host of progressive symptoms.

Leave a Reply

Your email address will not be published. Required fields are marked *